EGFR can upregulate the PD‐L1 pathway to control immune escape,7 and the combination of PD‐1/PD‐L1 inhibitors and EGFR TKIs is a good strategy to treat NSCLC with EGFR‐activating mutations.7RAS/TP53 mutations are more constantly found in NSCLC patients who showed PD‐L1 expression, which may provide a means to predict clinical efficacy of PD‐1/PD‐L1 inhibitors.46 Indeed, TP53 and EGFR mutations are strong parameters to predict responses to anti‐PD‐1 treatment in NSCLS.47 This evidence concerns the gene EGFR and non-small cell lung carcinoma.